Prostate cancer is the second most common malignant tumor among men. It often has an insidious onset and lacks specific clinical manifestations in the early stage. Most patients seek medical attention due to abnormal urination and are diagnosed through screening. Clinically, metastatic hormone–sensitive prostate cancer (mHSPC) with a huge pelvic mass as the initial manifestation is relatively rare. At present, the systemic treatment strategy of mHSPC has become a research hotspot in the field of advanced prostate cancer. This article reports a 66‐year‐old male patient who visited the orthopedics department due to unexplained low back pain. Lumbar MRI indicated a space‐occupying lesion in the pelvic cavity. The patient was then transferred to the urology department for abdominal CT examination, which revealed a mass approximately 12.0 × 8.9 × 9.4 cm in the pelvic cavity. The pathological diagnosis by puncture biopsy was prostate adenocarcinoma with pelvic metastasis. Based on the diagnosis and treatment process of this patient and the review of relevant literature, the aim is to provide a clinical evidence–based medical basis for individualized treatment and the exploration of new strategies for prostate cancer.
Yan et al. (Thu,) studied this question.